HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alglucerase. A review of its therapeutic use in Gaucher's disease.

Abstract
Alglucerase is a mannose-terminated form of human placental glucocerebrosidase, developed to treat patients with Gaucher's disease. Functional glucocerebrosidase is deficient in Gaucher's disease, an autosomal recessive lipid storage disorder that affects people of all ethnic backgrounds, but has a higher incidence among East European Jews (Ashkenazim). Gaucher's disease manifests with hepatosplenomegaly, bleeding disorders and bone disease, with the more rare subtypes (types 2 and 3) featuring neurological dysfunction. Prior to the development of enzyme replacement therapy, treatment for Gaucher's disease was mainly symptomatic relief. Primary treatment with glucocerebrosidase focuses on removal of the lipid metabolite that causes the pathology. Because of the rarity of Gaucher's disease clinical trials are small, and much of the data investigating alglucerase therapy have been obtained from studies of patients with type 1 disease, the prevalent subtype. Nonetheless, after intravenous administration of alglucerase, improvements are evident within 6 months of therapy. Patients have increased haemoglobin levels and platelet counts, and decreased incidences of epistaxis and bruising. Spleen and liver size are reduced, and skeletal parameters improve. Children gain height and most patients receiving alglucerase therapy are able to resume work and daily activities. Alglucerase is well tolerated, with few mild adverse reactions reported. Although the pharmacokinetic and pharmacodynamic information for alglucerase is limited, its unequivocal efficacy justifies enzyme replacement therapy with this compound as first-line treatment for patients with Gaucher's disease, for whom treatment options are limited.
AuthorsR Whittington, K L Goa
JournalDrugs (Drugs) Vol. 44 Issue 1 Pg. 72-93 (Jul 1992) ISSN: 0012-6667 [Print] New Zealand
PMID1379912 (Publication Type: Journal Article, Review)
Chemical References
  • Hemoglobins
  • alglucerase
  • Glucosylceramidase
Topics
  • Bone and Bones (drug effects, enzymology)
  • Brain (drug effects, enzymology)
  • Gaucher Disease (classification, drug therapy)
  • Glucosylceramidase (administration & dosage, deficiency, metabolism, pharmacokinetics, therapeutic use)
  • Hemoglobins (analysis)
  • Humans
  • Liver (drug effects, enzymology)
  • Platelet Count (drug effects)
  • Spleen (drug effects, enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: